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.2012.01.0Abstract The present investigation was aimed to establish a validated stability-indicating liquid
chromatographic method for the estimation of etoposide (ETP) in bulk drug and self-nano emulsi-
fying formulation. ETP was successfully separated from the degradation products formed under
stress conditions on LiChrospher 100 C18 reverse-phase column (a 250 mm · 4.6 mm i.d., 5-lm par-
ticle size) using 55:45 (v/v) acetonitrile–phosphate buffer saline (pH 4.5) as the mobile phase, at a
ﬂow rate of 1.0 mL min1 and detection at 283 nm. The response was a linear function of analyte
concentration (R2 > 0.9997) over the concentration range of 0.05–50 lg mL1. The method was
validated for precision, accuracy, robustness, sensitivity and speciﬁcity. The % recovery of ETP
at three different levels (50%, 100% and 150%) ranged between 93.84% and 100.06% in optimized
self-nano emulsifying formulation, Etosid soft-gelatin capsule and Fytosid injection. First-order
degradation kinetics of ETP were observed under acidic and alkaline conditions. The method was
also applied for the stability assessment of self-nano emulsifying formulation under accelerated con-
ditions, the formulation was found to be stable at all storage conditions with the shelf-life of
2.37 years at 25 C. The method holds promise for routine quality control of ETP in bulk, pharma-
ceutical formulations as well as in stability-indicating studies.
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051. Introduction
Etoposide (ETP), chemically designated as 40-demethylepipod-
ophyllotoxin-9-(4,6-O-ethylidene)-b-D-glucopyranoside, is an
important antineoplastic agent currently in clinical use for
the treatment of small cell lung cancer, testicular cancer and
lymphomas (Toffoli et al., 2004; Sissolak et al., 2010). Its
mechanism of action involves breakage of DNA strands by
reversible interaction with topoisomerase II (Hande, 2008).
Low and erratic oral absorption of ETP has been attributedier B.V. All rights reserved.
104 N. Akhtar et al.to drug precipitation in the gastrointestinal lumen due to poor
aqueous solubility, pH-related degradation and efﬂux by
p-glycoprotein transporter (Patlolla and Vobalaboina, 2005;
Tian et al., 2007; Bansal et al., 2009; Akhtar et al., 2011a).
In order to overcome the above mentioned constraints, self-
nanoemulsifying (SNE) formulation of ETP has been
developed and optimized in our laboratory. SNE formulation
comprises of isotropic mixtures of natural or synthetic oils,
solid or liquid surfactants, or alternatively, one or more hydro-
philic solvents and co-solvents/surfactants (Date et al., 2010).
A selective and sensitive stability-indicating analytical method
is required for the evaluation of ETP based novel drug delivery
system. Analytical methods such as high-performance liquid
chromatography (LC) coupled with UV detection (Shirazi
et al., 2001; Kato et al., 2003; Zhang et al., 2010), ﬂuorescence
detection (Robieux et al., 1996), electrochemical detection
(Eisenberg and Eickhoff, 1993; Duncan et al., 1986; Cai
et al., 1999) and solid-phase extraction (Manouilov et al.,
1998) have been previously reported for the determination of
ETP. However, most of these methods are not ideal for routine
measurements, since they necessitate tedious extraction proce-
dures in case of biological ﬂuids and exhibit long retention
times. Modern chromatographic method, such as LC-MS/
MS, differential pulse voltammetry and UPLC-qTOF-MS/
MS have also been developed to determine ETP level in biolog-
ical matrixes (Chen and Uckuna, 2000; Radi et al., 2007;
Sachin et al., 2010). However, these interfaces are extremely
complicated and quite expensive to be employed for routine
analysis. Moreover, these are not suitable for parent drug sta-
bility test guidelines issued by ICH.
The ICH guideline entitled ‘‘Stability testing of new drug
substances and products’’ requires stress testing to be carried
out in order to elucidate the inherent stability characteristics
of the active substance. These include various stress tests like
hydrolytic stability, oxidative stability and photolytic
stability testing (ICH, Q1A (R2), 2005). An ideal stability-
indicating analytical method should be able to quantify the
active constituents and at the same time resolve the drug
from its degradation products. This would also enable the
detection and measurement of the drug and its degradation
products in the presence of excipients employed in the
formulation. The literature is silent on the development of
a validated stability-indicating assay method in routine anal-
ysis of ETP in the presence of its degradation products.
Therefore, it was thought necessary to study the stability
of ETP under different stress conditions. The main objective
of the present manuscript was to develop and validate stabil-
ity-indicating high-performance liquid chromatographic
method for the determination of ETP in the presence of
its degradation products in accordance to ICH guidelines.
The proposed stability-indicating method is simple and al-
lows rapid for stability studies and quality control analysis
of drug in bulk, pharmaceutical formulations as well as in
stability-indicating studies. Moreover, the proposed LC
method was utilized to investigate the kinetics of this
antineoplastic agent under acidic and alkaline conditions at
different temperatures and their respective degradation
kinetic parameters were calculated with the help of Arrhenius
plot. The proposed LC method was also utilized for stability
assessment of the optimized self-nano emulsifying formula-
tion under accelerated conditions.2. Materials and methods
2.1. Materials
Etoposide was (assigned purity: 99.5%) originated as gift sam-
ple from the Dabur Research Foundation (Ghaziabad, India).
Marketed products (Etosid soft-gelatin capsule, claimed to
contain 50 mg and Fytosid injection, claimed to contain
20 mg mL1 of ETP) were commercially purchased. Sefsol
218 was gift sample from Nikko Chemicals (Japan). Transcutol
P was kindly provided by Gattefosse, France (Mumbai, India).
Cremophor RH 40 was achieved from BASF (Mumbai,
India). Triacetin was purchased from E-Merck (Mumbai,
India). HPLC-grade methanol and acetonitrile were obtained
from Spectrochem Pvt. Ltd. Mumbai, India. Buffers and other
chemicals were of analytical-reagent grade. Ultra-pure water
was obtained from a Milli-Q system (Millipore, USA).
2.2. Methodology
2.2.1. Standard solution
The stock solution of ETP was prepared by dissolving 10 mg in
20 mL methanol in a 100-mL volumetric ﬂask following
dilution to 100 mL with mobile phase. This solution was then
diluted as needed to prepare different standard solutions from
0.05 to 50 lg mL1. The quality control (QC) samples of ETP
at three different levels were independently prepared at
concentrations of low QC (LQC, 2 lg mL1), medium QC
(MQC, 10 lg mL1) and high QC (HQC, 40 lg mL1).
2.2.2. Optimized SNE, capsule and injection preparation
The self-nano emulsifying formulation of ETP was prepared
by aqueous titration (low energy emulsiﬁcation technique)
method (Shaﬁq et al., 2007; Azeem et al., 2009a). The compo-
sition of optimized SNE formulation of ETP (ETPSNE) was
28.57% (w/w) of sefsol 218 and Triacetin (1:1) (oil), 47.62%
(w/w) of Cremophor RH 40 (surfactant) and 23.81% (w/w)
of Transcutol P (co-surfactant). The optimized ETPSNE formu-
lation (label claim 50 mg), Etosid soft-gelatin capsule (label
claim 50 mg) and Fytosid injection (label claim 20 mg mL1)
with an appropriate volume of 300, 200 and 500 lL were suit-
ably diluted with methanol, respectively, to yield a stock con-
centration of 100 lg mL1. These solutions were sonicated for
10 min and further diluted with the mobile phase to yield a
concentration of 10 lg mL1. The above solutions were then
ﬁltered through a 0.22-lm nylon membrane ﬁlter and analyzed
in triplicate by proposed LC method.
2.2.3. Instrumentation and chromatographic conditions
The analysis was carried out on a Waters Alliance e 2695
separating module (Waters Co., MA, USA) using photo diode
array detector (waters 2998) with autosampler and column
oven. The instrument was controlled by the use of Empower
software installed with equipment for data collection and
acquisition. Compounds were separated at an ambient temper-
ature (25 ± 2 C), on a 250 mm · 4.6 mm i.d., 5-lm particle
size, LiChrospher 100 C18 reverse-phase column with 55:45
(v/v) acetonitrile–phosphate buffer saline (pH 4.5) as the
mobile phase at a ﬂow rate of 1.0 mL min1. Before use, the
mobile phase was ﬁltered through a 0.22-lm Nylon ﬁlter.
A validated stability-indicating LC method for estimation of etoposide 105The eluent was monitored at a wavelength of 283 nm. The
injection volume was 10 lL.
2.2.4. Method validation
Validation was done with respect to various parameters, as
required under ICH guideline (ICH, Q2 (R1), 2005). The line-
arity of the method was conﬁrmed using standard solution of
ETP at different concentrations of analytes within the range of
0.05–50 lg mL1. Each solution was analyzed in triplicate by
plotting the peak area against concentration. In method preci-
sion, intra-day (repeatability) and inter-day precision and
accuracy were determined by six replicate analyses of quality
control samples at concentrations of LQC (2 lg mL1),
MQC (10 lg mL1) and HQC (40 lg mL1) on the same day
and on three consecutive days, respectively. The precision
was expressed as the percentage coefﬁcient variation [CV
(%)] of measured concentrations for each calibration level,
whereas accuracy was expressed as percentage recovery
[(ETP found/ETP applied) · 100] (Faiyazuddin et al., 2011).
For the determination of % recovery, preanalyzed samples
were spiked with 50%, 100% and 150% of the ETP label claim
for each amount; six determinations were performed (Akhtar
et al., 2011b). This was done to check the recovery of the drug
at different levels in the ETPSNE and in marketed formula-
tions. In addition, the speciﬁcity was evaluated by analyzing
solutions containing the excipients employed for the prepara-
tion of ETPSNE. The system response was examined for the
presence of interference or overlaps with the ETP responses.
Robustness was studied to evaluate the effect of small but
deliberate variations in the chromatographic conditions at
three different levels, i.e. 1, 0, +1. One factor at a time
was changed to estimate the effect. The limits of detection
(LOD) and quantitation (LOQ) were calculated by the method
based on the standard deviation (r) of the responses for blank
samples in triplicate and the slope (S) of the calibration plot,
by use of the formulae LOD= 3.3r/S and LOQ= 10r/S.
The ruggedness of the method was assessed by the comparison
of intra-day and inter-day assay results for ETP obtained by
two analysts in the same laboratory (Azeem et al., 2009b).
2.2.5. Forced degradation studies
ICH guidelines explicitly require forced decomposition studies
to be conducted under a variety of conditions and separation of
the pure drug from its degradation products for stability-
indicating assay methods (ICH, Q6A,1999). In forced degrada-
tion studies, methanolic stock solution of ETP at concentration
of 100 lg mL1 was prepared. The acid- and base-induced
degradations were performed separately by transferring 2 mL
of methanolic solution of ETP (100 lg mL1) to a 10 mL
amber colored volumetric ﬂasks to which 8 mL of 0.1 M HCl
and 0.1 M NaOH were added, respectively. Both the ﬂasks
were sealed and heated under reﬂux at 80 C for 30 min. The
oxidative degradation was performed by transferring 2 mL of
the methanolic solution of ETP (100 lg mL1) to 10 mL amber
colored volumetric ﬂask to which 8 mL of H2O2 (20%, v/v) was
added. The ﬂask was sealed and heated under reﬂux at 80 C
for 30 min. UV-degradation was carried out according to
option 2 of Q1B in ICH guidelines (ICH, Q1B, 1996). Brieﬂy,
10 mL of methanolic solution of ETP (100 lg mL1) was trans-
ferred in a transparent volumetric ﬂask in a UV light cabinet
(Thermo-lab, India) and exposed to radiation at 320–400 nm
for 8 h at 25 C. After removal from the light cabinet, samplewas prepared for analysis by diluting to 5 lg mL1 with the
mobile phase. To assess dry-heat-induced degradation, pow-
dered drug was exposed to dry heat at 80 C/75 ± 5% RH,
in a convection oven for 8 h. The bulk drug sample was then
prepared for analysis by dilution to 5 lg mL1 with the mobile
phase. All the solutions were ﬁltered through a 0.22-lm nylon
membrane ﬁlter, before analyzing the solution into the chro-
matographic system.
2.2.6. Kinetic investigation
The logarithmic values of percentages of the remaining con-
centrations at different time intervals (0, 5 10, 15, 20 and
30 min) were used to establish the degradation plots of ETP
in 0.1 M HCl and 0.1 M NaOH solutions. In brief, 10 mL of
methanolic solution (100 lg mL1) of ETP was mixed with
10 mL of 0.1 M HCl and 0.1 M NaOH, separately, in
100 mL round bottomed (double neck) ﬂasks and heated under
reﬂux at 313, 328, and 343 K for 30 min. The reﬂuxed samples
(0.5 mL) were then transferred to 5-mL volumetric ﬂasks and
diluted with the mobile phase for analysis. The degradation ki-
netic parameters such as the degradation rate constant (Kdeg),
degradation half-life (t1/2) and shelf-life (t0.9) at 313, 328, and
343 temperatures (K) were derived from the plots. Each exper-
iment was done in triplicate and data were further processed
and degradation kinetic parameters were calculated. The pre-
dicted kinetic parameters for the degradation of ETP at
25 C were extrapolated from Arrhenius plot.
2.2.7. Stability studies
The optimized ETPSNE (label claim 50 mg) was subjected for
stability analysis by charging in stability chamber (Thermo
Lab, India) under accelerated conditions (30 ± 2 C/
65 ± 5% RH, 40 ± 2 C/65 ± 5% RH and 50 ± 2 C/
75 ± 5% RH). Following the protocol, the samples were with-
drawn at a time interval of 30, 60 and 90 days and analyzed for
% drug content. Analysis was carried out at each time interval
by taking 50 lL of each formulation, diluting it to 10 mL with
methanol and analyzing by LC system. The amount of drug
degraded and the amount remaining at each time interval were
calculated. The order of degradation was determined by the
graphical method. Degradation rate constant (Kdeg) was deter-
mined at each temperature. The Arrhenius plot was con-
structed between logK and 1/T to determine the shelf-life of
optimized ETPSNE formulation, where T is the absolute tem-
perature in degrees Kelvin. The value of K at 25 C (K25)
was obtained by extrapolation of the plot and shelf-life was
then calculated by substituting K25 in the following equation:
T0:9 ¼ 0:1052=K25
where T0.9 is the time required for 10% drug degradation is re-
ferred to as shelf-life.3. Results and discussion
3.1. Method development
The chromatographic conditions were optimized with a view
to develop a reverse-phase LC stability-indicating assay meth-
od. No internal standard was used because no extraction or
separation step was involved. The optimization of the method
development was done by ﬁxing one variable and changing the
106 N. Akhtar et al.other variables among mobile phase composition, ﬂow rate
and pH of the mobile phase. ETP is a hydrophobic molecule,
almost insoluble in aqueous solvents and freely soluble in
organic solvents, such as methanol and acetonitrile. Among
the different combinations for solvent system, acetonitrile
and phosphate buffer saline of pH 4.5, were preferred as the
mixture resulted in a greater response to ETP after several pre-
liminary investigatory runs. The pH of the mobile phase was
found to be critical. The peak obtained above pH 4.5, was
irregular and asymmetric. Increasing the buffer content
enhanced the tailing and decreased the plate count. Changes
in concentration of the organic modiﬁer often lead to signiﬁ-
cant changes in separation selectivity. Increasing the organic
modiﬁer content resulted in a decrease in the retention time
(RT) of the drug. Therefore, a high acetonitrile concentration
was used at a ﬂow rate of 1.0 mL min1, keeping in mind
the possibility that potential minor degradation products could
appear after stress studies and may co-elute with the drug
because of the reduced RT if the ﬂow rate was increased. The
peak shape and symmetry were found to be good when a
mobile phase composition of 55:45 (v/v) of acetonitrile–
phosphate buffer saline of pH 4.5, was used at a ﬂow rate
of 1.0 mL min1 at ambient temperature. Under these
conditions, the analyte peak was well-deﬁned with very goodFigure 1 Typical HPLC chromatogram
Table 1 Precision and accuracy data.
Parameters Applied (lg/mL) Found (lg
Intra-day precision 2 (LQC) 1.96 ± 0.
10 (MQC) 9.99 ± 0.
40 (HQC) 40.03 ± 0.
Inter-day precision 2 (LQC) 1.94 ± 0.
10 (MQC) 9.97 ± 0.
40 (HQC) 40.05 ± 0.
a Mean from six determinations (n= 6).
b Precision as a coefﬁcient of variation (CV %) = (Standard deviation
c Accuracy = (ETP found/ETP applied) · 100.symmetry, free from tailing and the RT of ETP was found to
be 4.519 ± 0.017 min. (Fig. 1). The method presents advanta-
ges over previously published methods (Manouilov et al., 1998;
Eisenberg and Eickhoff, 1993) by the usage of readily available
mobile phase acetonitrile and phosphate buffer saline with
photo diode array detector and short retention time enabled
the analysis of a large number of samples with a small quantity
of mobile phase, leading to its cost effectiveness.
3.2. Method validation
The correlation coefﬁcients (R2 > 0.9997) of the calibration
plots indicate good linearity in the range of 0.05–50 lg mL1.
The regression equation for the calibration plot was
y= 20,903x+ 739.47 (n= 3; detection at 283 nm). No signif-
icant difference was observed in the slopes of calibration plots
prepared on different days (ANOVA, P> 0.05). The intra-
day precision was found to be 61.581% (n= 6) and inter-
day precision over three different days was calculated as
62.113% (n= 6). Intra-day and inter-day accuracy were
found to be 98.00–100.07% and 97.00–100.12%, respectively.
The low CV values demonstrated precision of the method
(Table 1). The recovery of the method ranged from 93.84%
to 100.06% after spiking previously analyzed samples withof ETP; RT at 4.519 ± 0.017 min.
) ± SDa Precision (CV, %)b Accuracy (%)c
031 1.581 98.00
064 0.640 99.90
053 0.132 100.07
041 2.113 97.00
121 1.213 99.70
087 0.217 100.12
/ETP found) · 100.
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ranging from 1.05 to 2.29 also indicate the suitability of this
method for the analysis of ETPSNE formulation and commer-
cially available dosage forms (soft-gelatin capsule and injec-Figure 2 Chromatograms obtained for degradation products of ET
30 min at 80 C; degradation product (DP) peaks RT 2.057 and 3.527 m
at 80 C; degradation product (DP) peaks RT 1.823 and 5.541 min.
Table 2 % Recovery data.
Formulation (%) Theoretical (mg)a Added (mg)
ETPSNE (SNE formulation)
50 50 25
100 50
150 75
Etosid (soft-gelatin capsule)
50 50 25
100 50
150 75
Fytosid (injection)
50 20 10
100 20
150 30
a Units: mg per formulation.
b Mean from six determinations (n= 6).tion) (Table 2). RSD was found to be within limit, which
indicated that the proposed method was accurate. There was
no interaction observed between drug and excipients present
in the nanoemulsifying system, conﬁrmed the speciﬁcity ofP samples. (A) ETP sample degraded in 0.1 M HCl, reﬂuxed for
in. (B) ETP sample degraded in 0.1 M NaOH, reﬂuxed for 30 min
Detected (mg) Recovery (%)b RSD (%)
23.46 93.84 2.03
48.26 96.52 1.62
75.01 100.01 1.92
23.79 95.16 1.77
48.21 96.42 1.05
74.13 98.84 1.92
9.46 94.60 2.29
19.47 97.35 1.53
30.02 100.06 1.91
108 N. Akhtar et al.the method. The robustness of the method was investigated
under a variety of conditions with respect to changes in ﬂow
rate, pH and composition of mobile phase on the analysis of
10 lg mL1 standard solution samples. The peak area and
retention time obtained were in the range of (219,959 ±
1504.919 to 222,802 ± 1926.522) and (4.516 ± 0.023 to
4.518 ± 0.033 min), respectively, following intentional change
of ﬂow rate. The effect of change of pH was measured and the
peak area and retention time were achieved in the range of
(218,335 ± 1682.069 to 228,617 ± 1277.343) and (4.515 ±
0.022 to 4.520 ± 0.024 min), respectively. The results obtained
for the peak area and retention time were in the range of
(222,561 ± 1707.357 to 222,956 ± 2398.447) and (4.517 ±
0.031 to 4.519 ± 0.027 min), respectively, on deliberate change
in the composition of mobile phase. Low RSD values in the
range of 0.767–1.099% for these results substantiated the con-
sistency and robustness of the method. Hence, the method was
sufﬁciently robust for normally expected variations inFigure 3 Chromatograms obtained for degradation products of ETP
30 min at 80 C; degradation product (DP) peaks RT 2.191 and 5.532
degradation product (DP) peaks RT 2.251and 2.937 min.chromatographic conditions. The LOD and LOQ for ETP
were determined to be 4.7 and 11.6 ng mL1, respectively
which were quite lower than previously reported method (Shir-
azi et al., 2001), for which corresponding values were 20 and
40 ng mL1, respectively. The results strongly advocate that
developed method is more sensitive. RSD values for intra-
day and inter-day assay of ETP, performed in the same
laboratory by two analysts did not exceed 2.0%, indicating
the ruggedness of the method.
3.3. Forced degradation studies
The results from stress-testing studies were indicative of the
high speciﬁcity of the method. The method was capable of sep-
arating degradation products in the presence of pure drug.
Well-separated analyte and degradation peaks were obtained
in all the degradation experiments (Figs. 2 and 3) such as acid
degradation, base degradation, oxidative degradation andsamples. (A) ETP sample degraded in H2O2 (20% v/v), reﬂuxed for
min. (B) ETP sample degraded in UV320–400 nm, exposed for 8 h;
Table 4 Kinetic parameters under acidic and alkaline condition.
Condition Temperature (K) R Kdeg (min
1) t1/2 (min) t0.9 (min)
0.1 M HCl 313 0.9862 0.0094 73.393 11.141
328 0.9868 0.0241 28.658 4.350
343 0.9957 0.0637 10.863 1.649
0.1 M NaOH 313 0.9808 0.0135 51.002 7.742
328 0.9909 0.0373 18.574 2.819
343 0.9992 0.1043 6.642 1.018
R: correlation coefﬁcient, Kdeg: degradation rate constant.
Table 3 Forced degradation studies.
Exposure conditions Applied
(lg mL1)
ETP found
(lg)
CV
(%)
Remaining
(%)
RT value for
degradants*
Fig.
nos.
ETP-acid [0.1 M HCl; reﬂuxed at 80 C for 30 min] 10 0.847 ± 0.065 7.67 8.47 2.057, 3.527 Fig. 2A
ETP-base [0.1 M NaOH; reﬂuxed at 80 C for 30 min] 10 0.565 ± 0.031 5.48 5.65 1.823, 5.541 Fig. 2B
ETP-H2O2 [20% v/v; reﬂuxed at 80 C for 30 min] 10 1.503 ± 0.172 11.44 15.03 2.191, 5.532 Fig. 3A
ETP-UV [(320–400 nm); exposed for 8 h] 5 3.719 ± 0.481 12.93 74.38 2.251, 2.937 Fig. 3B
ETP-dry heat [exposed at 80 C/75 ± 5% RH] 5 4.127 ± 0.613 14.85 82.54 2.421 NS**
* RT: value in min.
** NS: not shown.
 Coefﬁcient of variation (CV %) = (Standard deviation/ETP found) · 100.
A validated stability-indicating LC method for estimation of etoposide 109photo degradation, respectively. The molecule was found to be
labile to acid degradation, base degradation, oxidative degra-
dation and photo degradation with maximum susceptibility
to alkaline degradation. In acidic hydrolysis the ETP was
found to degrade by approximately 91.53% with one major
degradation product (DP1) and one minor product (DP2),
which were well separated at RT 2.057 and 3.527 min, respec-
tively (Fig. 2A). The drug was found to be highly labile to
alkaline hydrolysis. On heating the drug solution in 0.1 M
NaOH at 80 C for 30 min, 94.35% degradation was seen with
the appearance of two degradation products at RT 1.823 min
and 5.541 min, respectively (Fig. 2B). The drug showed liabil-
ity to hydrogen peroxide at 80 C. It decomposed to an extent
of 84.97% in 20% H2O2 in 30 min. The degradation pattern
was found to be similar to alkaline conditions and two degra-
dants were well eluted at approximately 2.191 and 5.532 min,
respectively (Fig. 3A). Decomposition was also detected on
the exposure of ETP solution to light in a UV-stability cham-
ber with two minor degradation products (DP1 and DP2) at
RT 2.251 and 2.937 min, respectively (Fig. 3B), indicating that
the drug sample was also susceptible to UV-photolytic stress.
Even under dry-heat conditions, a loss of 17.46% of the
ETP was noted within 8 h, which obviously is not a negligible
quantity. Summary of the degradation studies of drug is given
in Table 3.
The most favorable pH range for ETP stability is pH 4–6.
At a pH < 4, hydrolysis of the glycosidic linkage and the lac-
tone ring occurs, and at a pH > 6, epimerization to the less ac-
tive cis-ETP and intra molecular ester hydrolysis into the salt
of the cis hydroxy acid resulted (Holthuis et al., 1989). The de-
graded products which are produced under stress conditions
could be either isomers of parent drug or its hydroxy acidderivatives. It was not the intention of the study to identify
degradation products but merely to authenticate that they
would not interfere in the analysis if and when present. To con-
clude, it can be stated that none of the peaks that could be gen-
erated by the stress treatment interfered with the peak
corresponding to the active component, showing the method
is selective and suitable for routine work.
3.4. Kinetic investigation
The kinetic of degradation of ETP was investigated in 0.1 M
HCl and 0.1 M NaOH. A constant reduction in the concentra-
tion of ETP with increasing time intervals was observed. At the
selected temperatures the degradation process of ETP was con-
ﬁrmed by ﬁrst-order kinetics. The ﬁrst-order rate constant (K),
half-life (t1/2), and shelf-life (t0.9) were determined at each tem-
perature for acidic and alkaline degradation (Table 4). First-
order kinetics data were ﬁtted to the Arrhenius equation:
logK ¼ log A Ea=2:303 RT
where K is the rate constant, A the frequency factor, Ea the
activation energy, R the gas constant (1.987 cal/K/mol), and
T the absolute temperature. The Arrhenius plot of logK
against reciprocal temperature (1/T · 103) was found to be lin-
ear in the temperature range studied. The degradation rate
constants for acidic and alkaline conditions at room tempera-
ture (25 ± 1 C) were calculated to be 0.1854 and 0.2484 h1,
respectively. The ﬁrst-order t1/2 and t0.9 under acidic condi-
tions at 25 C were found to be 224.28 and 34.04 min, respec-
tively, and for alkaline condition they were found to be 167.58
and 25.44 min, respectively. The ﬁrst-order degradation kinet-
ics revealed higher values of the degradation rate constants
Table 5 Stability study.
Time (Days) Storage conditions ETPSNE formulation Slope · 104 Kdeg · 104 (days1) t0.9 (year)
Found (mg) % Remained log % remained
0 30 ± 2 C/65 ± 5% RH 50.00 100.00 2.000 0.6500 1.4969 1.93
30 49.79 99.58 1.998
60 49.57 99.14 1.996
90 49.33 98.66 1.994
0 40 ± 2 C/65 ± 5% RH 50.00 100.00 2.000 1.6612 3.8258 0.75
30 49.42 98.84 1.995
60 48.85 97.70 1.990
90 48.31 96.62 1.985
0 50 ± 2 C/75 ± 5% RH 50.00 100.00 2.000 2.0770 4.7834 0.60
30 49.25 98.50 1.993
60 48.62 97.24 1.988
90 47.87 95.74 1.981
RH: relative humidity.
110 N. Akhtar et al.with shorter half-life in 0.1 M NaOH solution compared with
0.1 M HCl solutions. It was concluded that the drug was more
susceptible to alkaline degradation, with shorter t1/2 than for
acidic degradation (Table 4).
3.5. Stability studies
Table 5 illustrates slow degradation of ETP at each tempera-
ture indicating considerable stability of ETP in the SNE for-
mulation. The order of degradation was determined by
graphical method at each temperature which was found to
be ﬁrst order. Therefore, for ﬁrst order degradation, log% of
drug remaining was plotted against time and degradation rate
constant (Kdeg) was calculated from the slope of the curve at
each temperature (Table 5). At 25 C, the degradation rate
constant (Kdeg) and shelf-life of optimized ETPSNE formula-
tion were found to be 1.2173 · 104 (days1) and 2.37 years,
respectively.
4. Conclusions
A validated stability-indicating LC method was developed for
ETP in bulk drug and self-nano emulsifying formulation. All
degradants were well resolved from the pure drug with signif-
icant differences in their values for retention time. The method
was found to be speciﬁc as the peaks of the degradation prod-
ucts did not interfere with the ETP peak. Degradation kinetic
studies showed higher degradation rates and a shorter half-life
under alkaline solution as compared to acidic solution. The
optimized nano formulation was found to be stable through-
out the analysis at all temperature and humidity conditions.
The developed method could be adopted for the routine anal-
ysis of samples generated during stability studies of ETP and
its formulations.
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